Cite
Abstract 3775: Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response
MLA
Guy de Martynoff, et al. “Abstract 3775: Use of RLI-15 a Clinical Grade Fusion Protein with IL-15 Superagonistic Activity for the Activation of Anti-Tumor Immune Response.” Cancer Research, vol. 78, July 2018, p. 3775. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........4a848a9c0a72078e1eefa5c494a9699b&authtype=sso&custid=ns315887.
APA
Guy de Martynoff, Ulrich Moebius, Romana Mikyšková, David Bechard, Marek Kovar, Nada Hradilova, Milan Reiniš, Irena Adkins, Jakub Tomala, Lenka Sadilkova, Barbora Tomalova, & Radek Spisek. (2018). Abstract 3775: Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response. Cancer Research, 78, 3775.
Chicago
Guy de Martynoff, Ulrich Moebius, Romana Mikyšková, David Bechard, Marek Kovar, Nada Hradilova, Milan Reiniš, et al. 2018. “Abstract 3775: Use of RLI-15 a Clinical Grade Fusion Protein with IL-15 Superagonistic Activity for the Activation of Anti-Tumor Immune Response.” Cancer Research 78 (July): 3775. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........4a848a9c0a72078e1eefa5c494a9699b&authtype=sso&custid=ns315887.